- Home
- RLYB vs IMMX Comparison
RLYB vs IMMX Comparison
Compare RLYB & IMMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RLYB
- IMMX
- Stock Information
- Founded
- RLYB 2018
- IMMX 2014
- Country
- RLYB United States
- IMMX United States
- Employees
- RLYB N/A
- IMMX N/A
- Industry
- RLYB Biotechnology: Pharmaceutical Preparations
- IMMX Medicinal Chemicals and Botanical Products
- Sector
- RLYB Health Care
- IMMX Health Care
- Exchange
- RLYB Nasdaq
- IMMX Nasdaq
- Market Cap
- RLYB 42.3M
- IMMX 46.8M
- IPO Year
- RLYB 2021
- IMMX 2021
- Fundamental
- Price
- RLYB $0.99
- IMMX $1.68
- Analyst Decision
- RLYB Buy
- IMMX Strong Buy
- Analyst Count
- RLYB 6
- IMMX 1
- Target Price
- RLYB $8.10
- IMMX $7.00
- AVG Volume (30 Days)
- RLYB 70.0K
- IMMX 89.1K
- Earning Date
- RLYB 11-07-2024
- IMMX 11-12-2024
- Dividend Yield
- RLYB N/A
- IMMX N/A
- EPS Growth
- RLYB N/A
- IMMX N/A
- EPS
- RLYB N/A
- IMMX N/A
- Revenue
- RLYB $598,000.00
- IMMX N/A
- Revenue This Year
- RLYB N/A
- IMMX N/A
- Revenue Next Year
- RLYB N/A
- IMMX $200.00
- P/E Ratio
- RLYB N/A
- IMMX N/A
- Revenue Growth
- RLYB N/A
- IMMX N/A
- 52 Week Low
- RLYB $0.95
- IMMX $1.26
- 52 Week High
- RLYB $3.46
- IMMX $7.75
- Technical
- Relative Strength Index (RSI)
- RLYB 43.03
- IMMX 50.69
- Support Level
- RLYB $0.96
- IMMX $1.65
- Resistance Level
- RLYB $1.15
- IMMX $1.93
- Average True Range (ATR)
- RLYB 0.06
- IMMX 0.16
- MACD
- RLYB -0.00
- IMMX 0.01
- Stochastic Oscillator
- RLYB 19.30
- IMMX 42.55
About RLYB Rallybio Corporation
Rallybio Corp is a clinical stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders. Its program is for the prevention of fetal and neonatal alloimmune thrombocytopenia, a potentially life-threatening rare disease that can cause uncontrolled bleeding in fetuses and newborns.
About IMMX Immix Biopharma Inc.
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.